BAXTER INTERNATIONAL INC BAX
Surgical & Medical Instruments & Apparatus · NYSE
Umsatz
$10.36B
+3.0% Jahresübergangsrate
Nettoerlös
$2.66B
+209.2% Jahresübergangsrate
Gesamtvermögen
$25.78B
-8.8% Jahresübergangsrate
EPS
5.23
+208.3% Jahresübergangsrate
Advertisement
Einkommensrechnung
| Zeitraum | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Revenues | $8.27B | $5.43B | $2.62B | $10.36B | $7.88B | $5.18B | $2.49B | $10.06B |
| Gross Profit | $2.80B | $1.85B | $861.00M | $4.15B | $3.02B | $1.99B | $961.00M | $3.55B |
| R&D Expense | $392.00M | $274.00M | $140.00M | $518.00M | $379.00M | $250.00M | $120.00M | $450.00M |
| SG&A Expense | $2.13B | $1.42B | $703.00M | $2.95B | $2.21B | $1.45B | $729.00M | $3.10B |
| Operating Income (Loss) | $421.00M | $249.00M | $58.00M | $707.00M | $449.00M | $294.00M | $115.00M | $-2.85B |
| Interest Expense | — | — | — | $508.00M | — | — | — | $413.00M |
| Net Income (Loss) | $171.00M | $217.00M | $126.00M | $2.66B | $-137.00M | $-277.00M | $37.00M | $-2.43B |
| EPS (Diluted) | 0.33 | 0.42 | 0.25 | 5.23 | -0.27 | -0.54 | 0.07 | -4.83 |
Bilanz
| Zeitraum | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $20.05B | $20.05B | $20.05B | $25.78B | $25.78B | $25.78B | $25.78B | $28.28B |
| Current Assets | $6.87B | $6.87B | $6.87B | $8.85B | $8.85B | $8.85B | $8.85B | $9.60B |
| Cash & Equivalents | $1.73B | $1.69B | $2.29B | $3.08B | $1.42B | $1.57B | $2.83B | $1.62B |
| Accounts Receivable | $1.86B | $1.86B | $1.86B | $1.68B | $1.68B | $1.68B | $1.68B | $1.72B |
| Inventory | $2.23B | $2.23B | $2.23B | $2.05B | $2.05B | $2.05B | $2.05B | $1.92B |
| PP&E (Net) | $2.91B | $2.91B | $2.91B | $2.87B | $2.87B | $2.87B | $2.87B | $2.87B |
| Goodwill | $4.93B | $4.93B | $4.93B | $5.28B | $5.28B | $5.28B | $5.28B | $5.79B |
| Total Liabilities | $13.95B | $13.95B | $13.95B | $18.76B | $18.76B | $18.76B | $18.76B | $19.81B |
| Current Liabilities | $2.97B | $2.97B | $2.97B | $6.51B | $6.51B | $6.51B | $6.51B | $6.50B |
| Accounts Payable | $999.00M | $999.00M | $999.00M | $968.00M | $968.00M | $968.00M | $968.00M | $881.00M |
| Long-Term Debt | — | — | — | $9.44B | — | — | — | $13.18B |
| Stockholders Equity | $6.13B | $6.13B | $6.13B | $6.96B | $6.96B | $6.96B | $6.96B | $8.40B |
Kassenfluss
| Zeitraum | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $261.00M | $24.00M | $-193.00M | $1.73B | $531.00M | $278.00M | $163.00M | $1.21B |
| Investing Cash Flow | $3.04B | $3.15B | $3.27B | $3.21B | $-421.00M | $-257.00M | $-166.00M | $-931.00M |
| Financing Cash Flow | $-4.07B | $-3.99B | $-3.23B | $-3.49B | $-1.22B | $-1.08B | $-140.00M | $-1.44B |
| Stock Repurchases | — | — | — | — | — | — | — | $32.00M |
Ähnliche Firmen
BECTON DICKINSON & CO
BDX
BOSTON SCIENTIFIC CORP
BSX
DEXCOM INC
DXCM
3M CO
MMM
INSULET CORP
PODD
RESMED INC
RMD
Solventum Corp
SOLV
STRYKER CORP
SYK
Mehr erfahren
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Daten stammen aus der öffentlichen Datenbank des US-amerikanischen SEC EDGAR. Diese Seite bietet keine Anlageberatung.